Loss-of-function variants in CIDEB were associated with a reduced risk of liver disease of any cause (OR, 0.67; 95% CI, 0.57–0.79) and lower risk of HCC (OR, 0.51; 95% CI, 0.26–1) in an exome-wide association analysis that compared participants with various types of liver diseases with controls without liver disease, analyzing multiple biobanks in Europe, United States, and UK.117. Here, CIDEB is linked to liver disorder.